In Rupiah billion | In SGD million* | |||||||
2020 Actual (Restated**) |
2021 Actual (Restated**) |
2022 Actual | 2020 Actual (Restated**) |
2021 Actual (Restated**) |
2022 Actual | |||
Revenue | 14,475 | 19,659 | 17,797 | 1,344 | 1,826 | 1,653 | ||
Gross profit | 2,919 | 5,073 | 4,559 | 271 | 471 | 423 | ||
Gain/(loss) arising from changes in fair value of biological assets | 3 | 113 | (136) | 0.3 | 10 | (13) | ||
Profit from operations | 1,479 | 2,826 | 2,702 | 137 | 263 | 251 | ||
Net profit after tax | 164 | 1,287 | 1,318 | 15 | 119 | 122 | ||
Profit attributable to owners of the Company | 20 | 759 | 770 | 2 | 71 | 72 | ||
EPS (in Rp)/(in SGD ‘cents) | 14 | 544 | 552 | 0.1 | 5.1 | 5.2 | ||
Current assets | 7,808 | 9,550 | 10,552 | 670 | 819 | 905 | ||
Fixed assets | 19,374 | 18,527 | 18,136 | 1,662 | 1,589 | 1,556 | ||
Other non-current assets | 10,292 | 9,559 | 9,578 | 883 | 820 | 822 | ||
Total assets | 37,474 | 37,636 | 38,266 | 3,214 | 3,228 | 3,282 | ||
Current liabilities | 9,204 | 9,970 | 9,883 | 789 | 855 | 848 | ||
Non-current liabilities | 7,755 | 6,230 | 5,231 | 665 | 534 | 449 | ||
Total liabilities | 16,959 | 16,200 | 15,114 | 1,455 | 1,389 | 1,296 | ||
Shareholders' equity | 11,353 | 11,601 | 12,900 | 974 | 995 | 1,106 | ||
Total equity | 20,515 | 21,436 | 23,152 | 1,760 | 1,839 | 1,986 | ||
Total debt | 11,356 | 10,334 | 9,144 | 974 | 886 | 784 | ||
Cash | 2,446 | 3,764 | 4,422 | 210 | 323 | 379 | ||
In Percentage (%) | ||||||||
Sales growth/(decline) | 6.0% | 35.8% | (9.5%) | |||||
Gross profit margin | 20.2% | 25.8% | 25.6% | |||||
Profit from operations margin | 10.2% | 14.4% | 15.2% | |||||
Net profit after tax margin | 1.1% | 6.5% | 7.4% | |||||
Profit attributable to owners of the Company margin |
0.1% | 3.9% | 4.3% | |||||
Return on assets1 | 3.9% | 7.5% | 7.1% | |||||
Return on equity2 | 0.2% | 6.5% | 6.0% | |||||
Current ratio (times) | 0.8 | 1.0 | 1.1 | |||||
Net debt to equity ratio (times)3 | 0.43 | 0.31 | 0.20 | |||||
Total debt to total assets ratio (times) | 0.30 | 0.27 | 0.24 |
1 Profit from operations divided by total assets
2 Profit attributable to owners of the Company divided by shareholders’ equity
3 Net debt divided by total equity
* For ease of reference, 2020 to 2022 Income Statement and Balance Sheet items are converted at exchange rates of 10,767/SGD1 and Rp11,659/SGD1, respectively.
** The restated figures were related to the application of IFRIC Agenda Decision on SFRS(I) 1-19 Employee Benefits.